Century Therapeutics Announces Its Addition to the Russell Microcap® Index
June 24, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
June 21, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022
June 06, 2022 07:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 16, 2022 07:30 ET
|
Century Therapeutics, Inc.
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 following IND submission in mid 2022- - Ended first quarter 2022 with cash, cash...
Century Therapeutics to Present at Upcoming Investor Conferences
May 03, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at the ASGCT 25th Annual Meeting
May 02, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
April 18, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference
March 23, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates
March 17, 2022 07:30 ET
|
Century Therapeutics, Inc.
IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submission Entered into a strategic...